Product Name: Plecanatide
Form: Free base
CAS No: 467426-54-6
Molar Mass: 1681.89
Chemical Formula: C65H104N18O26S4
Synonyms: Trulance, Guanilib
Storage: Store at -20℃
Sequence: NDECELCVNVACTGCL
Target: guanylate cyclase-C
Application:
Plecanatide (CAS: 467426-54-6) is a synthetic analog of uroguanylin, a natural peptide hormone involved in regulating intestinal fluid and electrolyte balance. It functions as a guanylate cyclase-C (GC-C) agonist, specifically targeting GC-C receptors in the gastrointestinal tract. Plecanatide activates GC-C receptors, leading to increased intracellular levels of cyclic guanosine monophosphate (cGMP), which in turn stimulates chloride and bicarbonate secretion into the intestinal lumen, promoting fluid secretion and bowel movement. Plecanatide is used in the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), providing relief from constipation symptoms and improving bowel habits. In pharmaceutical chemistry, plecanatide's targeted activation of GC-C receptors represents a novel approach to managing constipation, offering an effective and well-tolerated treatment option for patients with CIC and IBS-C. Its application underscores its importance in gastrointestinal therapeutics and improving quality of life for individuals with chronic constipation. Additionally, ongoing research explores plecanatide's potential in other gastrointestinal disorders characterized by dysregulated intestinal motility and fluid balance, highlighting its versatility in gastroenterology.
Current Research:
Plecanatide is a synthetic guanylate cyclase-C (GC-C) agonist that is used primarily for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It functions as a novel and effective therapeutic agent, promoting bowel movement and improving symptoms associated with constipation-related disorders. Plecanatide acts locally in the gastrointestinal tract, increasing fluid secretion and motility, which helps in alleviating the discomfort caused by constipation and improving the quality of life for patients suffering from these chronic conditions.
Mechanism of Action
Plecanatide works by binding to and activating the GC-C receptor on the surface of intestinal epithelial cells. This receptor activation leads to increased intracellular cyclic guanosine monophosphate (cGMP) levels, which, in turn, stimulates chloride and bicarbonate ion secretion into the intestinal lumen. The influx of water into the gut softens stool and enhances bowel motility, leading to increased stool frequency and improved passage. Additionally, plecanatide has a localized action in the gastrointestinal tract, meaning it does not have systemic effects, which reduces the risk of side effects compared to other laxatives or medications affecting motility.
Indications and Uses
Plecanatide is approved for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. CIC is characterized by infrequent or difficult bowel movements, often accompanied by abdominal discomfort or bloating. IBS-C, a subtype of irritable bowel syndrome, involves similar symptoms but also includes additional issues such as abdominal pain. Plecanatide helps to relieve these symptoms by enhancing bowel movement frequency, reducing abdominal discomfort, and promoting the passage of stool. The drug is administered orally, typically once daily, and provides a convenient and effective option for managing these gastrointestinal conditions.
Efficacy and Clinical Benefits
Plecanatide has shown strong efficacy in clinical trials for both CIC and IBS-C. In pivotal studies, patients treated with plecanatide experienced a significant increase in weekly bowel movement frequency and a reduction in abdominal discomfort compared to placebo. Additionally, patients reported improvements in stool consistency and a reduction in bloating. The drug's ability to improve both stool frequency and overall digestive comfort makes it a valuable treatment option for individuals with chronic constipation-related disorders. Plecanatide has also demonstrated a good safety profile in clinical trials, with most side effects being mild and transient.
Safety and Tolerability
Plecanatide is generally well tolerated, with a safety profile that is favorable for most patients. The most common adverse effects reported include diarrhea, abdominal pain, and flatulence. These side effects are typically mild and occur more frequently during the initial stages of treatment. Serious side effects are rare, but like other medications that affect gastrointestinal motility, plecanatide should be used with caution in patients with a history of gastrointestinal obstruction or related issues. Patients are also advised to monitor for dehydration symptoms, particularly if diarrhea occurs. Plecanatide’s mechanism of action is localized to the intestines, which reduces the risk of systemic side effects such as changes in blood pressure or heart rate, making it a relatively safe option for long-term use.
Advantages and Limitations
One of the primary advantages of plecanatide is its localized action, which results in minimal systemic exposure and fewer side effects compared to traditional laxatives and other gastrointestinal treatments. This makes it a suitable option for chronic management of constipation disorders. Plecanatide also targets both stool frequency and associated abdominal discomfort, providing a comprehensive solution for patients with CIC and IBS-C. However, like all medications, it has some limitations. Diarrhea is a common side effect, particularly during the early stages of treatment, which may limit its use in certain populations. Additionally, its efficacy may vary among individuals, and some patients may require adjunct therapies to achieve optimal relief from their symptoms.
Future Directions
Ongoing research is focused on further understanding the long-term safety and efficacy of plecanatide, especially in diverse patient populations, including those with coexisting conditions such as inflammatory bowel disease (IBD) or diabetes. There is also interest in exploring plecanatide’s potential for treating other gastrointestinal disorders where motility and fluid secretion play a key role, such as in opioid-induced constipation (OIC). Additionally, researchers are investigating combination therapies that could enhance plecanatide’s effectiveness or broaden its indications for other functional gastrointestinal disorders. Personalized treatment approaches, based on specific patient characteristics or symptom profiles, could further optimize the use of plecanatide.
Reference:
Al-Salama, Z. T., & Syed, Y. Y. (2017). Plecanatide: first global approval. Drugs, 77, 593-598.
Get a Quote
LinkPeptide
